DE4035455A1 - ENANTIOMER SEPARATION - Google Patents
ENANTIOMER SEPARATIONInfo
- Publication number
- DE4035455A1 DE4035455A1 DE19904035455 DE4035455A DE4035455A1 DE 4035455 A1 DE4035455 A1 DE 4035455A1 DE 19904035455 DE19904035455 DE 19904035455 DE 4035455 A DE4035455 A DE 4035455A DE 4035455 A1 DE4035455 A1 DE 4035455A1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- sulfinyl
- pyridinyl
- methoxy
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Die Erfindung betrifft ein Verfahren zur Auftrennung von chiralen Pyridylme thylsulfinyl-1H-benzimidazolen in ihre Enantiomeren. Die Enantiomeren werden in der pharmazeutischen Industrie zur Herstellung von Medikamenten verwendet.The invention relates to a process for the separation of chiral pyridylme thylsulfinyl-1H-benzimidazoles in their enantiomers. The enantiomers are in used in the pharmaceutical industry to manufacture medicines.
In einer Vielzahl von Patentanmeldungen und Patenten werden Pyridylmethylsulfinyl-1H-benzimidazole beschrieben, die magensäuresekretionshemmende Eigenschaften besitzen. Im Zusammenhang mit der vorliegenden Erfindung seien hier beispielsweise die folgenden Patentanmeldungen und Patente erwähnt: EP-B-5 129, EP-A-1 34 400 (= USP 45 55 518), EP-A-1 27 763 (=USP 45 60 693), EP-B-1 66-287 (=USP 47 58 579), EP-A-1 74 726, EP-A-2 01 575 (=USP 46 86 230), WO89/05 299 und WO89/11 479. - Es ist weiterhin bekannt, daß diese Pyridylmethylsulfinyl-1H- benzimidazole ein Chiralitätszentrum besitzen und daß sie daher in ihre Enantiomeren trennbar sein sollten. Trotz der Vielzahl von Patentanmeldungen auf dem Gebiet der Pyridylmethylsulfinyl-1H-benzimidazole ist bisher jedoch noch kein Verfahren beschrieben worden, mit dessen Hilfe die Pyridylmethylsulfinyl- 1H-benzimidazole in die optischen Antipoden getrennt werden könnten. Auch die Enantiomeren der Pyridylmethylsulfinyl-1H-benzimidazole sind bisher (mangels eines geeigneten Trennverfahrens) noch nicht isoliert und charakterisiert worden.In a large number of patent applications and patents, pyridylmethylsulfinyl-1H-benzimidazoles described the gastric acid secretion-inhibiting properties have. In connection with the present invention, for example mentions the following patent applications and patents: EP-B-5 129, EP-A-1 34 400 (= USP 45 55 518), EP-A-1 27 763 (= USP 45 60 693), EP-B-1 66-287 (= USP 47 58 579), EP-A-1 74 726, EP-A-2 01 575 (= USP 46 86 230), WO89 / 05 299 and WO89 / 11 479. It is also known that these pyridylmethylsulfinyl-1H- Benzimidazoles have a chiral center and that they are therefore in their enantiomers should be separable. Despite the large number of patent applications However, the field of pyridylmethylsulfinyl-1H-benzimidazoles is still so far no method has been described by means of which the pyridylmethylsulfinyl 1H-benzimidazoles could be separated into the optical antipodes. Also the Enantiomers of pyridylmethylsulfinyl-1H-benzimidazoles have so far (lack of a suitable separation process) has not yet been isolated and characterized.
Es wurde nun ein Verfahren gefunden, mit dessen Hilfe die nachstehend näher bezeichneten Pyridylmethylsulfinyl-1H-benzimidazole in ihre optischen Antipoden gespalten werden können.A method has now been found by means of which those described in more detail below Pyridylmethylsulfinyl-1H-benzimidazoles in their optical antipodes can be split.
Das Verfahren ist dadurch gekennzeichnet, daß man Verbindungen der Formel I, The process is characterized in that compounds of the formula I
worin
R1 Wasserstoff, 1-4C-Alkyl oder 1-4C-Alkoxy bedeutet,
R2 Wasserstoff, Trifluormethyl, 1-4C-Alkyl, 1-4C-Alkoxy, ganz oder überwiegend
durch Fluor substituiertes 1-4C-Alkoxy. Chlordifluormethoxy,
2-Chlor-1,1,2-trifluormethoxy oder gemeinsam mit R3 gewünschtenfalls ganz
oder teilweise durch Fluor substituiertes 1-2C-Alkylendioxy oder
Chlortrifluorethylendioxy bedeutet,
R3 Wasserstoff, 1-4C-Alkyl, 1-4C-Alkoxy, ganz oder überwiegend durch Fluor
substituiertes 1-4C-Alkoxy, Chlordifluormethoxy, 2-Chlor-1,1,2-trifluorethoxy
oder gemeinsam mit R2 gewünschtenfalls ganz oder teilweise durch
Fluor substituiertes 1-2C-Alkylendioxy oder Chlortrifluorethylendioxy bedeutet,
R4 Wasserstoff oder 1-4C-Alkyl bedeutet,
R5 Wasserstoff, 1-4C-Alkyl oder 1-4C-Alkoxy bedeutet und
R6 1-4C-Alkoxy, ganz oder überwiegend durch Fluor substituiertes 1-4C-Alkoxy
oder Benzyloxy bedeutet,
oder ihre Salze mit Basen mit konfigurativ einheitlich chiralen Verbindungen
der Formel II,wherein
R1 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy,
R2 is hydrogen, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy. Chlorodifluoromethoxy, 2-chloro-1,1,2-trifluoromethoxy or together with R3, if desired, completely or partially means fluorine-substituted 1-2C-alkylenedioxy or chlorotrifluoroethylenedioxy,
R3 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly substituted by fluorine-1-4C-alkoxy, chlorodifluoromethoxy, 2-chloro-1,1,2-trifluoroethoxy or together with R2 if desired in whole or in part by fluorine substituted 1-2C-alkylenedioxy or chlorotrifluoroethylene dioxy means
R4 represents hydrogen or 1-4C-alkyl,
R5 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy and
R6 denotes 1-4C-alkoxy, completely or predominantly substituted by fluorine-substituted 1-4C-alkoxy or benzyloxy,
or their salts with bases with configuratively uniform chiral compounds of the formula II,
Rchi-X (II)Rchi-X (II)
worin Rchi einen konfigurativ einheitlichen, chiralen Rest und X eine Abgangsgruppe darstellt, umsetzt, das erhaltene Isomeren- bzw. Diastereomerengemisch III, where Rchi is a configuratively uniform, chiral residue and X is a leaving group represents, implemented, the mixture of isomers or diastereomers obtained III,
worin R1, R2, R3, R4, R5 und R6 die oben angegebenen Bedeutungen haben und Rchi einen konfigurativ einheitlichen, chiralen Rest darstellt, trennt und aus den optisch reinen Diastereomeren die konfigurativ einheitlichen, optisch reinen Verbindungen I durch Solvolyse in stark saurem Medium freisetzt.wherein R1, R2, R3, R4, R5 and R6 have the meanings given above and Rchi represents a configuratively uniform, chiral residue, separates and from the optically pure diastereomers the configuratively uniform, optically pure Releases compounds I by solvolysis in a strongly acidic medium.
1-4C-Alkyl steht für geradkettige oder verzweigte Alkylreste; beispielsweise seien der Butyl-, i-Butyl-, sec.-Butyl-, t-Butyl-, Propyl-, Isopropyl-, Ethyl- und insbesondere der Methylrest genannt.1-4C-alkyl represents straight-chain or branched alkyl radicals; for example be the butyl, i-butyl, sec.-butyl, t-butyl, propyl, isopropyl, ethyl and especially called the methyl radical.
1-4C-Alkoxy steht für geradkettige oder verzweigte Alkoxyreste; beispielsweise seien genannt der Butoxy-, i-Butoxy-, sec.-Butoxy-, t-Butoxy-, Propoxy-, Isopropoxy-, Ethoxy- und insbesondere der Methoxyrest.1-4C-alkoxy represents straight-chain or branched alkoxy radicals; for example the butoxy, i-butoxy, sec.-butoxy, t-butoxy, propoxy, isopropoxy, Ethoxy and especially the methoxy residue.
Als ganz oder überwiegend durch Fluor substituiertes 1-4C-Alkoxy seien beispielsweise der 1,2,2,-Trifluorethoxy-, der 2,2,3,3,3-Pentafluorpropoxy-, der Perfluorethoxy- und insbesondere der 1,1,2,2-Tetrafluorethoxy-, der Trifluormethoxy-, der 2,2,2-Trifluorethoxy- und der Difluormethoxyrest genannt.Examples of all or predominantly fluorine-substituted 1-4C-alkoxy are the 1,2,2, -trifluoroethoxy-, the 2,2,3,3,3-pentafluoropropoxy-, the Perfluoroethoxy and in particular 1,1,2,2-tetrafluoroethoxy, trifluoromethoxy, the 2,2,2-trifluoroethoxy and the difluoromethoxy radical called.
Wenn R2 und R3 gemeinsam ganz oder teilweise durch Fluor substituiertes 1-2C-Alkylendioxy oder Chlortrifluorethylendioxy bedeuten, so sind die Substituenten R2 oder R3 in Nachbarpositionen am Benzoteil des Benzimidazolringes gebunden.When R2 and R3 together are partially or completely substituted by fluorine-substituted 1-2C-alkylenedioxy or chlorotrifluoroethylene dioxy, the substituents R2 or R3 bound in neighboring positions on the benzo part of the benzimidazole ring.
Als ganz oder teilweise durch Fluor substituiertes 1-2C-Alkylendioxy seien beispielsweise der 1,1-Difluorethylendioxy- (-O-CF₂-CH₂-O-), der 1,1,2,2-Tetrafluorethylendioxy- (-O-CF₂-CF₂-O-) und insbesondere der Difluormethylendioxy- (-O-CF₂-O-) und der 1,1,2-Trifluorethylendioxyrest (-O-CF₂-CHF-O-) genannt. Examples of all or part of fluorine-substituted 1-2C-alkylenedioxy are the 1,1-difluoroethylene dioxy- (-O-CF₂-CH₂-O-), the 1,1,2,2-tetrafluoroethylene dioxy- (-O-CF₂-CF₂-O-) and especially the difluoromethylene dioxy- (-O-CF₂-O-) and the 1,1,2-trifluoroethylene dioxyrest (-O-CF₂-CHF-O-) called.
Als Verbindungen der Formel II kommen prizipiell alle chiralen, konfigurativ einheitlichen Verbindungen in Frage, die mit der Verbindung I oder ihrem Anion unter Abspaltung der Abgangsgruppe X zu reagieren in der Lage sind und deren Rest Rchi nach der Diastereomerentrennung glatt und ohne unerwünschte Nebenreaktion wieder abgespalten werden kann.In principle, all chiral, configurative compounds come as compounds of the formula II unitary compounds in question, those with compound I or its anion are able to react with separation of the leaving group X and their Rest Rchi smooth after diastereomer separation and without undesirable side reaction can be split off again.
Als Abgangsgruppen X kommen insbesondere alle nucleophil ablösbaren Atome oder Gruppen, wie beispielsweise Halogenatome (J, Br oder insbesondere Cl) oder durch Veresterung (z. B. mit Sulfonsäuren) aktivierte Hydroxylgruppen (-O-SO₂-CH₃, -O-SO₂-CF₃ oder -O-SO₂-C₆H₄-p-CH₂) in Frage.All nucleophilically removable atoms or Groups such as halogen atoms (J, Br or especially Cl) or hydroxyl groups activated by esterification (e.g. with sulfonic acids) (-O-SO₂-CH₃, -O-SO₂-CF₃ or -O-SO₂-C₆H₄-p-CH₂) in question.
Als Reste Rchi kommen alle konfigurativ einheitlichen Reste in Frage, die sich von natürlich vorkommenden oder synthetisch zugänglichen chiralen Verbindungen ableiten lassen und die solvolytisch unter sauren Bedingungen aus den Verbindungen III abgespalten werden können. Als Reste Rchi seien insbesondere genanntAll configuratively uniform residues that can be considered as residues Rchi of naturally occurring or synthetically accessible chiral compounds can be derived and the solvolytically under acidic conditions from the compounds III can be split off. Rchi may be mentioned in particular as residues
- - Glycosylreste, die sich von Glycopyranosen, Glycofuranosen oder Oligosacchariden ableiten und die gewünschtenfalls mit in der Kohlenhydratchemie üblichen Schutzgruppen teilweise oder vollständig geschützt sind, oder- Glycosyl residues, which are derived from glycopyranoses, glycofuranoses or oligosaccharides derive and if desired with in carbohydrate chemistry usual protective groups are partially or fully protected, or
- - chirale, über das Sauerstoffatom verknüpfte Terpenalkoholreste, oder- chiral terpene alcohol residues linked via the oxygen atom, or
- - andere chirale, über das Sauerstoffatom verknüpfte Alkoholreste,- other chiral alcohol residues linked via the oxygen atom,
die jeweils an dem als Verknüpfungsglied fungierenden Sauerstoffatom eine Carbonylgruppe oder insbesondere eine Methylengruppe tragen.each have a carbonyl group on the oxygen atom functioning as a linking member or especially carry a methylene group.
Bevorzuge Reste Rchi sind Reste der Formel IVPreferred radicals Rchi are radicals of the formula IV
R′-O-CH₂-(IV)R′-O-CH₂- (IV)
worin R′ gemeinsam mit dem Sauerstoffatom, woran es gebunden ist, einen Glycosylrest, einen chiralen Terpenalkoholrest, oder einen sonstigen chiralen Alkoholrest darstellt.wherein R 'together with the oxygen atom to which it is attached is a glycosyl radical, a chiral terpene alcohol residue, or another chiral alcohol residue represents.
Als Glycosylreste R′-O- seien beispielsweise die Reste genannt, die sich von natürlich vorkommenden Mono- oder Disacchariden, wie Arabinose, Fructose, Galactose, Glucose, Lactose, Mannose, Ribose, Xylose, Maltose, Sorbose oder N-Acetyl-D-glucosamin herleiten. As glycosyl residues R'-O-, for example, the residues are mentioned, which differ from naturally occurring mono- or disaccharides, such as arabinose, fructose, galactose, Glucose, lactose, mannose, ribose, xylose, maltose, sorbose or Derive N-acetyl-D-glucosamine.
Als chirale Terpenalkoholreste R′-O- seien insbesondere solche Reste genannt, die sich von einem natürlich vorkommenden oder synthetisch leicht zugänglichen Terpenalkohol herleiten. Als beispielhafte Terpenalkohole seien hierbei genannt: Isopulegol, Neomenthol, Isomenthol, Menthol, Carveol, Dihydrocarveol, Terpinen-4-ol, Mirtenol, Citronellol, Isoborneol, Borneol, Isopinocampheol und insbesondere Fenchol.As chiral terpene alcohol residues R′-O-, such residues may be mentioned in particular which are of a naturally occurring or synthetically easily accessible Derive terpene alcohol. Exemplary terpene alcohols are: Isopulegol, neomenthol, isomenthol, menthol, carveol, dihydrocarveol, Terpinen-4-ol, Mirtenol, Citronellol, Isoborneol, Borneol, Isopinocampheol and especially fenchol.
Als sonstige chirale Alkoholreste R′-O- seien beispielsweise die Reste genannt, die sich von folgenden Alkoholen herleiten: Mandelsäureester, Cinchonidin, Cinchonin, Ephedrin, Serinmethylester, Sitosterol, 3-Hydroxy-2-methyl-propionsäuremethylester und Milchsäureethylester.Other chiral alcohol residues R′-O- which may be mentioned are, for example, which are derived from the following alcohols: mandelic acid ester, cinchonidine, cinchonine, Ephedrine, serine methyl ester, sitosterol, 3-hydroxy-2-methyl-propionic acid methyl ester and lactic acid ethyl ester.
Ein besonders bevorzugter Rest Rchi ist der Fenchyloxymethylrest.A particularly preferred radical Rchi is the fenchyloxymethyl radical.
Die Umsetzung der Verbindung I mit der Verbindung II erfolgt auf eine dem Fachmann vertraute Weise. Zur Erhöhung der Nucleophilie der Verbindungen I ist es zweckmäßig, diese zu deprotonieren, d. h. von den Salzen der Verbindungen I mit Basen auszugehen. Als Beispiele für basische Salze seien Natrium-, Kalium-, Calcium-, Aluminium-, Magnesium-, Titan-, Ammonium- oder Guanidiniumsalze erwähnt, die beispielsweise durch Umsetzung der Verbindungen I mit den entsprechenden Hydroxiden (z. B. Natriumhydroxid oder Kaliumhydroxid) auf übliche Weise erhalten werden können.The reaction of compound I with compound II is carried out by a person skilled in the art familiar way. It is to increase the nucleophilicity of compounds I. expedient to deprotonate them, d. H. of the salts of compounds I with Bases to go out. Examples of basic salts are sodium, potassium, Calcium, aluminum, magnesium, titanium, ammonium or guanidinium salts mentioned, which, for example, by reacting the compounds I with the corresponding ones Hydroxides (e.g. sodium hydroxide or potassium hydroxide) in the usual way can be obtained.
Die Umsetzung der Verbindungen I mit Verbindungen II wird in inerten, protischen oder aprotischen Lösungsmitteln durchgeführt. Als solche eignen sich beispielsweise Methanol, Isopropanol, Dimethylsulfoxid, Aceton, Acetonitril, Dioxan, Dimethylformamid und vorzugsweise N-Methylpyrrolidon.The reaction of the compounds I with compounds II is carried out in inert, protic or aprotic solvents. Suitable as such are, for example Methanol, isopropanol, dimethyl sulfoxide, acetone, acetonitrile, dioxane, Dimethylformamide and preferably N-methylpyrrolidone.
Die Umsetzung wird - in Abhängigkeit von der Reaktivität der Verbindung II - vorzugsweise bei Temperaturen zwischen -30°C und +100°C, insbesondere bei Temperaturen zwischen 0°C und 50°C durchgeführt.The reaction is - depending on the reactivity of the compound II - preferably at temperatures between -30 ° C and + 100 ° C, especially at temperatures between 0 ° C and 50 ° C.
Die Trennung des nach der Umsetzung von I mit II erhaltenen Diastereomerengemisches erfolgt in an sich bekannter Weise, beispielsweise durch Chromatographie an geeigneten Säulen oder vorzugsweise durch fraktionierte Kristallisation.The separation of the mixture of diastereomers obtained after the reaction of I with II is carried out in a manner known per se, for example by chromatography on suitable columns or preferably by fractional crystallization.
Aufgrund der Prototropie im Benzimidazolteil der Verbindungen I (die 5- und 6- Positionen einerseits bzw. die 4- und 7-Positionen andererseits sind zueinander identisch) entstehen bei der Umsetzung mit den Verbindungen II bei entsprechendem Substitutionsmuster im Benzimidazol Isomerengemische. Zweckmäßigerweise werden die Isomeren noch vor Trennung der Diastereomeren voneinander getrennt, beispielsweise durch Säulenchromatographie an geeignetem Trägermaterial (z. B. Kieselgel) und mit geeigneten Elutionsmitteln (z. B. Ethylacetat).Due to the prototropy in the benzimidazole part of the compounds I (the 5- and 6- Positions on the one hand and the 4- and 7-positions on the other are mutually related identical) arise during the reaction with the compounds II with the corresponding Substitution Patterns in Benzimidazole Isomer Mixtures. Conveniently the isomers are separated from one another before the diastereomers are separated, for example by column chromatography on a suitable carrier material (e.g. Silica gel) and with suitable eluents (e.g. ethyl acetate).
Die Freisetzung der konformativ einheitlichen Verbindungen I aus den optisch reinen Diastereomeren III erfolgt durch Solvolyse unter stark sauren Bedingungen. Als für die Solvolyse geeignete Reagenzien seien beispielsweise starke höherkonzentrierte Säuren (z. B. 60-100%ige Schwefelsäure, konzentrierte Salzsäure, wasserfreie oder wasserhaltige Tetrafluorborsäure, Methansulfonsäure, Trifluormethansulfonsäure, Phosphorsäure oder Perchlorsäure), bevorzugt ca. 90%ige Schwefelsäure genannt. Die Freisetzung erfolgt vorzugsweise bei Temperaturen zwischen 0° und 40°C. Bei der auf die Freisetzung folgenden Aufarbeitung wird vorteilhafterweise so verfahren, daß der pH-Wert möglichst rasch erhöht wird, beispielsweise durch Einbringen der stark sauren Lösung in Pufferlösung oder bevorzugt in Lauge.The release of the conformatively uniform compounds I from the optically pure diastereomers III are carried out by solvolysis under strongly acidic conditions. Reagents suitable for solvolysis are, for example, strong ones higher concentrated acids (e.g. 60-100% sulfuric acid, concentrated hydrochloric acid, anhydrous or water-containing tetrafluoroboric acid, methanesulfonic acid, Trifluoromethanesulfonic acid, phosphoric acid or perchloric acid), preferably about 90% Called sulfuric acid. The release takes place preferably at temperatures between 0 ° and 40 ° C. In the workup following the release is advantageously carried out so that the pH increases as quickly as possible is, for example by introducing the strongly acidic solution in buffer solution or preferably in lye.
Die Verbindungen der Formel II sind bekannt bzw. sie sind auf eine für den Fachmann vertraute Weise aus bekannten Verbindungen auf analoge Weise zugänglich. So können beispielsweise die Verbindungen II, in denen Rchi die Bedeutung der Formel IV hat und X ein Chloratom darstellt, durch Chlormethylierung entsprechender Alkohole [z. B. in Analogie zu R. C. Ronald et. al., J. Org. Chem. 45 (1980) 2224] hergestellt werden.The compounds of formula II are known or they are based on one for the A person familiar with the art is accessible in an analogous manner from known compounds. For example, the compounds II in which Rchi has the meaning of the formula IV and X represents a chlorine atom, correspondingly by chloromethylation Alcohols [e.g. B. in analogy to R. C. Ronald et. al., J. Org. Chem. 45 (1980) 2224].
Die Verbindungen der Formel III sind neu und ebenfalls Gegenstand der Erfindung.The compounds of formula III are new and also a subject of the invention.
Die konfigurativ einheitlichen, optisch reinen Verbindungen der Formel I sind ebenfalls neu und daher auch Gegenstand der Erfindung.The configuratively uniform, optically pure compounds of the formula I are also new and therefore also the subject of the invention.
Als beispielhafte, durch das erfindungsgemäße Verfahren herstellbare, optisch reine Verbindungen der Formel I und als dazugehörige erfindungsgemäße Zwischenprodukte III seien anhand der Substituentenbedeutungen in den obenstehenden Formeln I bzw. III die folgenden Verbindungen der nachstehenden Tabelle 1 besonders erwähnt: As an example, optically producible by the method according to the invention pure compounds of the formula I and as associated intermediates III according to the invention be based on the substituent meanings in the above Formulas I and III in particular the following compounds of Table 1 below mentioned:
Besonders bevorzugte, durch das erfindungsgemäße Verfahren herstellbare Verbindungen sind die VerbindungenParticularly preferred compounds that can be produced by the method according to the invention are the connections
(+)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1H-benz
imidazol,
(-)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1H-benz
imidazol,
(+)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benz
imidazol,
(-)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benz
imidazol,
(+)-2-{[(3-Methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl}sulfinyl-1H-benz
imidazol, und
(-)-2-{[(3-Methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl}sulfinyl-1H-benz
imidazol,(+) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(-) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(+) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(-) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(+) - 2 - {[(3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl} sulfinyl-1H-benz imidazole, and
(-) - 2 - {[(3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl} sulfinyl-1H-benz imidazole,
und ihre Salze mit Basen.and their salts with bases.
Die folgenden Beispiele dienen der näheren Erläuterung der Erfindung. Die Abkürzung h steht für Stunde(n), Schmp. für Schmelzpunkt.The following examples serve to explain the invention in more detail. The abbreviation h stands for hour (s), mp for melting point.
Zu einer Lösung von 50 g (0,123 Mol) (±)-5-Difluormethoxy-2-{[(3,4-dimeth oxy-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazol-Na-Salz in 125 ml N-Methylpyrrolidon tropft man bei einer Temperatur von 25-35°C innerhalb einer Stunde 27,5 g (0,136 Mol) (+)-Fenchyl-chlormethylether zu. Nach 6 h wird mit 500 ml Wasser verdünnt, der pH-Wert auf 9,0 gestellt und dreimal mit je 100 ml Dichlormethan extrahiert. Die vereinigten organischen Phasen werden mit Wasser gewaschen, getrocknet und im Vakuum vollständig eingeengt. Der ölige Rückstand wird an Kieselgel chromatographiert (Laufmittel: Ethylacetat). Man isoliert 25,2 g (74%) eines Diastereomerengemisches aus (+)- und (-)-5-Difluormethoxy- 2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1-[(+)-fenchyloxymethyl]-benzimidazol als blaßgelbes, allmählich kristallisierendes Öl (Rf.-Wert in Ethylacetat ca. 0,85). Viermalige Umkristallisation aus Ethylacetat/Diisopropylether liefert die Titelverbindung (9,0 g 71,4%) in Form farbloser Kristalle vom Schmp. 138-139°C {[α] = +155,2° (c=1, Chloroform)}.To a solution of 50 g (0.123 mol) of (±) -5-difluoromethoxy-2 - {[(3,4-dimeth oxy-2-pyridinyl) methyl] sulfinyl} -1H-benzimidazole Na salt in 125 ml of N-methylpyrrolidone one drips at a temperature of 25-35 ° C within an hour 27.5 g (0.136 mol) of (+) - fenchyl chloromethyl ether. After 6 h with 500 ml Diluted water, adjusted the pH to 9.0 and three times with 100 ml dichloromethane extracted. The combined organic phases are with water washed, dried and completely concentrated in vacuo. The oily residue is chromatographed on silica gel (eluent: ethyl acetate). One isolates 25.2 g (74%) of a diastereomer mixture of (+) - and (-) - 5-difluoromethoxy 2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1 - [(+) - fenchyloxymethyl] benzimidazole as a pale yellow, gradually crystallizing oil (Rf. value in ethyl acetate 0.85). Four recrystallizations from ethyl acetate / diisopropyl ether provides the title compound (9.0 g 71.4%) in the form of colorless crystals of M.p. 138-139 ° C {[α] = + 155.2 ° (c = 1, chloroform)}.
1,0 g (1,8 mMol) (+)-4-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]- sulfinyl}-1-[(+)-fenchyloxymethyl]-benzimidazol werden portionsweise bei 5-10°C unter Rühren in 7 ml 90%ige Schwefelsäure eingetragen. Nach vollständiger Auflösung wird das Reaktionsgemisch unter Kühlung in 8N Natronlauge eingetropft, der pH auf 7,5 gestellt und mehrmals mit Dichlormethan extrahiert. Die vereinigten Extrakte werden mit Wasser gewaschen, über Magnesiumsulfat getrocknet und im Vakuum vollständig eingeengt. Der rote ölige Rückstand wird über Kieselgel chromatographiert (Dichlormethan/Methanol) und anschließend aus Diisopropylether kristallisiert. Man erhält 0,3 g (44%) der Titelverbindung als farbloses Kristallisat vom Schmp. 147-148°C (Zers.) {[α] = +146,0° (c=0,5, Acetonitril/Methanol 1 : 1)}. 1.0 g (1.8 mmol) (+) - 4-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] - sulfinyl} -1 - [(+) - fenchyloxymethyl] benzimidazole are added in portions at 5-10 ° C entered with stirring in 7 ml of 90% sulfuric acid. After more complete Dissolution, the reaction mixture is dropped in 8N sodium hydroxide solution while cooling, the pH was adjusted to 7.5 and extracted several times with dichloromethane. The combined extracts are washed with water, dried over magnesium sulfate and completely concentrated in vacuo. The red oily residue becomes over Chromatographed silica gel (dichloromethane / methanol) and then out Diisopropyl ether crystallized. 0.3 g (44%) of the title compound are obtained as colorless crystals of mp. 147-148 ° C (dec.) {[α] = + 146.0 ° (c = 0.5, acetonitrile / methanol 1: 1)}.
Nach der in Beispiel 1 beschriebenen Arbeitsweise erhält man durch Umsetzung von 28 g (0,069 Mol) (±)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl- methyl]sulfinyl⟩-1H-benzimidazol-Na-Salz mit 16,5 g (0,084 Mol) (-)-Fenchyl chlormethylether in 75 ml N-Methylpyrrolidon nach Chromatographie an Kieselgel (Dichlormethan/Methanol) 11,0 (58%) eines Diastereomerengemisches aus (+)- und (-)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl}-1- [(-)-fenchyloxymethyl]-benzimidazol. Mehrmalige Umkristallisation aus Ethylacetat/ Diisopropylether liefert die Titelverbindung in Form farbloser Kristalle (4,0 g, 72%) vom Schmp. 138-139°C {[α] = -152,8° (c=1, Chloroform)}.The procedure described in Example 1 is obtained by implementation of 28 g (0.069 mol) (±) -5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl- methyl] sulfinyl⟩-1H-benzimidazole Na salt with 16.5 g (0.084 mol) of (-) - fenchyl chloromethyl ether in 75 ml of N-methylpyrrolidone after chromatography on silica gel (Dichloromethane / methanol) 11.0 (58%) of a mixture of diastereomers from (+) - and (-) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1- [(-) - fenchyloxymethyl] benzimidazole. Repeated recrystallization from ethyl acetate / Diisopropyl ether provides the title compound in the form of colorless crystals (4.0 g, 72%) mp 138-139 ° C {[α] = -152.8 ° (c = 1, chloroform)}.
Nach der in Beispiel 2 beschriebenen Arbeitsweise erhält man aus 1 g (1,8 mMol) (-)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1-[(-)- fenchyloxymethyl]-benzimidazol in 7 ml 90%iger Schwefelsäure 0,25 g (36%) der Titelverbindung vom Schmp. 144-145°C (Zers.) {[α] = -144,4° (c=0,5, Acetonitril/Methanol 1 : 1)}.Following the procedure described in Example 2, 1 g (1.8 mmol) is obtained (-) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1 - [(-) - fenchyloxymethyl] benzimidazole in 7 ml 90% sulfuric acid 0.25 g (36%) the title compound of mp 144-145 ° C (dec.) {[α] = -144.4 ° (c = 0.5, acetonitrile / methanol 1: 1)}.
Nach der in Beispiel 1 beschriebenen Arbeitsweise erhält man aus (±)-5- Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazol-Na-Salz (60 mMol) in 80 ml N-Methylpyrrolidon nach Chromatographie an Kieselgel (Ethylacetat) nach mehrmaliger Umkristallisation aus Ethylacetat/Diisopropylether 3,1 g (40%) der Titelverbindung in Form farbloser Kristalle vom Schmp. 161°C (Zers.) {[α] = +103,0° (c=1, Chloroform)}. According to the procedure described in Example 1, (±) -5- Methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benzimidazole Na salt (60 mmol) in 80 ml of N-methylpyrrolidone after chromatography on silica gel (Ethyl acetate) after repeated recrystallization from ethyl acetate / diisopropyl ether 3.1 g (40%) of the title compound in the form of colorless crystals of Mp 161 ° C (dec.) {[Α] = + 103.0 ° (c = 1, chloroform)}.
Nach der in Beispiel 2 beschriebenen Arbeitsweise erhält man aus 0,51 g (1 mMol) (+)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}- 1H-[(+)-fenchyloxymethyl]-benzimidzol in 4 ml 90%iger Schwefelsäure 0,15 g (43%) der Titelverbindung als amorphen Feststoff {[α] = +165° (c=0,5, Chloroform)}. According to the procedure described in Example 2, 0.51 g is obtained (1 mmol) (+) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} - 1H - [(+) - fenchyloxymethyl] benzimidzole in 4 ml of 90% sulfuric acid 0.15 g (43%) of the title compound as an amorphous solid {[α] = + 165 ° (c = 0.5, chloroform)}.
Nach dem erfindungsgemäßen Verfahren können Pyridylmethylsulfinyl-1H-benzimidazole erstmals in ihre optischen Antipoden aufgespalten werden. Als besonders überraschend ist hierbei die Tatsache zu werten, daß die Freisetzung der optisch reinen Verbindungen aus den Diastereomeren mit Hilfe hochkonzentrierter Mineralsäuren vorgenommen wird, obwohl bekannt ist, daß es sich bei den Pyridylmethylsulfinyl-1H-benzimidazolen um sehr säurelabile Verbindungen handelt.According to the process of the invention, pyridylmethylsulfinyl-1H-benzimidazoles be split into their optical antipodes for the first time. As special What is surprising here is the fact that the release of the optical pure compounds from the diastereomers with the help of highly concentrated Mineral acids is made, although it is known that the Pyridylmethylsulfinyl-1H-benzimidazoles are very acid-labile compounds.
Die erfindungsgemäß hergestellten Verbindungen werden als Wirkstoffe in Arzneimitteln für die Behandlung von Magen- und Darmerkrankungen eingesetzt. Bezüglich der Anwendungsweise und Dosierung der Wirkstoffe wird z. B. auf das europäische Patent 1 66 287 verwiesen.The compounds produced according to the invention are used as active ingredients in medicinal products used for the treatment of gastric and intestinal diseases. In terms of the application and dosage of the active ingredients is such. B. European Patent 1,666,287.
Claims (6)
R1 Wasserstoff, 1-4C-Alkyl oder 1-4C-Alkoxy bedeutet,
R2 Wasserstoff, Trifluormethyl, 1-4C-Alkyl, 1-4C-Alkoxy, ganz oder überwiegend durch Fluor substituiertes 1-4C-Alkoxy. Chlordifluormethoxy, 2-Chlor-1,1,2-trifluormethoxy oder gemeinsam mit R3 gewünschtenfalls ganz oder teilweise durch Fluor substituiertes 1-2C-Alkylendioxy oder Chlortrifluorethylendioxy bedeutet,
R3 Wasserstoff, 1-4C-Alkyl, 1-4C-Alkoxy, ganz oder überwiegend durch Fluor substituiertes 1-4C-Alkoxy, Chlordifluormethoxy, 2-Chlor-1,1,2-trifluorethoxy oder gemeinsam mit R2 gewünschtenfalls ganz oder teilweise durch Fluor substituiertes 1-2C-Alkylendioxy oder Chlortrifluorethylendioxy bedeutet,
R4 Wasserstoff oder 1-4C-Alkyl bedeutet,
R5 Wasserstoff, 1-4C-Alkyl oder 1-4C-Alkoxy bedeutet und
R6 1-4C-Alkoxy, ganz oder überwiegend durch Fluor substituiertes 1-4C-Alkoxy oder Benzyloxy bedeutet,
und ihre Salze mit Basen.1. Configuratively uniform, optically pure compounds of the formula I wherein
R1 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy,
R2 is hydrogen, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy. Chlorodifluoromethoxy, 2-chloro-1,1,2-trifluoromethoxy or together with R3, if desired, completely or partially means fluorine-substituted 1-2C-alkylenedioxy or chlorotrifluoroethylenedioxy,
R3 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly substituted by fluorine-1-4C-alkoxy, chlorodifluoromethoxy, 2-chloro-1,1,2-trifluoroethoxy or together with R2 if desired in whole or in part by fluorine substituted 1-2C-alkylenedioxy or chlorotrifluoroethylene dioxy means
R4 represents hydrogen or 1-4C-alkyl,
R5 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy and
R6 denotes 1-4C-alkoxy, completely or predominantly substituted by fluorine-substituted 1-4C-alkoxy or benzyloxy,
and their salts with bases.
(+)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(-)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(+)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(-)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(+)-2-{[(3-Methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl}sulfinyl-1H-benz imidazol, und
(-)-2-{[(3-Methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl}sulfinyl-1H-benz imidazol,
und ihren Salze mit Basen.2. A compound according to claim 1 selected from the group consisting of
(+) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(-) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(+) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(-) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(+) - 2 - {[(3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl} sulfinyl-1H-benz imidazole, and
(-) - 2 - {[(3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl} sulfinyl-1H-benz imidazole,
and their salts with bases.
(+)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(-)-5-Difluormethoxy-2-{[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(+)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(-)-5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benz imidazol,
(+)-2-{[(3-Methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl}sulfinyl-1H-benz imidazol, und
(-)-2-{[(3-Methyl-4-(2,2,2-trifluorethoxy)-2-pyridinyl]methyl}sulfinyl-1H-benz imidazol,
oder ihr Salz mit Basen herstellt.4. The method according to claim 3, characterized in that a compound selected from the group consisting of
(+) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(-) - 5-difluoromethoxy-2 - {[(3,4-dimethoxy-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(+) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(-) - 5-methoxy-2 - {[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl} -1H-benz imidazole,
(+) - 2 - {[(3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl} sulfinyl-1H-benz imidazole, and
(-) - 2 - {[(3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl] methyl} sulfinyl-1H-benz imidazole,
or you make salt with bases.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19904035455 DE4035455A1 (en) | 1990-11-08 | 1990-11-08 | ENANTIOMER SEPARATION |
AU88406/91A AU8840691A (en) | 1990-11-08 | 1991-11-06 | Separation of enantiomers |
PCT/EP1991/002096 WO1992008716A1 (en) | 1990-11-08 | 1991-11-06 | Separation of enantiomers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19904035455 DE4035455A1 (en) | 1990-11-08 | 1990-11-08 | ENANTIOMER SEPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
DE4035455A1 true DE4035455A1 (en) | 1992-05-14 |
Family
ID=6417839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19904035455 Withdrawn DE4035455A1 (en) | 1990-11-08 | 1990-11-08 | ENANTIOMER SEPARATION |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU8840691A (en) |
DE (1) | DE4035455A1 (en) |
WO (1) | WO1992008716A1 (en) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024867A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
WO1994025028A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole |
WO1994027988A1 (en) * | 1993-05-28 | 1994-12-08 | Astra Aktiebolag | Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds |
WO1995032958A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel substituted benzimidazoles |
WO1995032959A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel dialkoxy-pyridinyl-benzimidazole derivatives |
WO1996002535A1 (en) * | 1994-07-15 | 1996-02-01 | Astra Aktiebolag | Process for synthesis of substituted sulphoxides |
WO1997002261A1 (en) * | 1995-07-03 | 1997-01-23 | Astra Aktiebolag | A process for the optical purification of enantiomerically enriched benzimidazole derivatives |
US5776765A (en) * | 1994-11-28 | 1998-07-07 | Astra Aktiebolag | Method for preparing a pharmaceutically active enantiomeric or enantiomerically enriched sulfoxide compound by enantioselective bioreduction of a racemate sulfoxide compound |
US5840552A (en) * | 1994-11-28 | 1998-11-24 | Astra Aktiebolag | Preparation of pharmaceutically active compounds by biooxidation |
US5900424A (en) * | 1993-07-09 | 1999-05-04 | Astra Aktiebolag | Omeprazole magnesium salt form |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
WO2004080961A2 (en) * | 2003-03-12 | 2004-09-23 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous solids of pantoprazole and processes for their preparation |
WO2005012289A1 (en) * | 2003-07-17 | 2005-02-10 | Altana Pharma Ag | Novel salt of (r) - pantoprazole |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
WO2005105786A1 (en) * | 2004-04-28 | 2005-11-10 | Hetero Drugs Limited | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
WO2005116011A1 (en) * | 2004-05-28 | 2005-12-08 | Hetero Drugs Limited | A novel stereoselective synthesis of benzimidazole sulfoxides |
WO2006099810A1 (en) | 2005-03-25 | 2006-09-28 | Livzon Pharmaceutical Group Inc. | Substituted sulfoxide compounds, methods for preparing the same and use thereof |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7411070B2 (en) | 1997-05-30 | 2008-08-12 | Astrazeneca Ab | Form of S-omeprazole |
US7507829B2 (en) | 2002-12-19 | 2009-03-24 | Teva Pharmaceuticals Industries, Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
US7569697B2 (en) | 1999-06-17 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US7683177B2 (en) | 2003-06-10 | 2010-03-23 | Teva Pharmaceutical Industries Ltd | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
US7777044B2 (en) | 2005-03-03 | 2010-08-17 | Esteve Quimica, S.A. | Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1′-binaphthalene-2,2′diol |
US7799925B2 (en) | 2005-12-28 | 2010-09-21 | Unión Químico Farmacéutica, S.A. | Process for the preparation of the (S)-enantiomer of omeprazole |
EP2264024A1 (en) | 2008-10-14 | 2010-12-22 | LEK Pharmaceuticals d.d. | Process for the preparation of enantiomerically enriched proton pump inhibitors |
WO2011058569A1 (en) | 2009-11-12 | 2011-05-19 | Hetero Research Foundation | Process for the resolution of omeprazole |
US8173158B2 (en) | 2007-10-12 | 2012-05-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treating gastrointestinal disorders independent of the intake of food |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8222422B2 (en) | 2008-03-10 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Crystal of benzimidazole compound |
US8354541B2 (en) | 2008-11-18 | 2013-01-15 | Hetero Research Foundation | Optical purification of esomeprazole |
US8394963B2 (en) | 2007-02-21 | 2013-03-12 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
US8404853B2 (en) | 2006-07-05 | 2013-03-26 | Lupin Limited | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds |
US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US8697097B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
US8754108B2 (en) | 2000-11-22 | 2014-06-17 | Takeda, GmbH | Freeze-dried pantoprazole preparation and pantoprazole injection |
US8945621B2 (en) | 2009-06-25 | 2015-02-03 | Pozen Inc. | Method for treating a patient at risk for developing an NSAID-associated ulcer |
US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
RU2726320C1 (en) * | 2020-02-09 | 2020-07-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) | Method for determining omeprazole impurity components |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4504000A (en) * | 1993-04-27 | 2000-09-07 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
SE510666C2 (en) * | 1996-12-20 | 1999-06-14 | Astra Ab | New Crystal Modifications |
IL136249A0 (en) * | 1997-12-08 | 2001-05-20 | Byk Gulden Lomberg Chem Fab | Suppository containing an acid-labile active compound |
JP2002501896A (en) * | 1998-01-30 | 2002-01-22 | セプラコール, インク. | S-lansoprazole compositions and methods |
EP1056456A4 (en) * | 1998-01-30 | 2006-10-25 | Sepracor Inc | R-lansoprazole compositions and methods |
IL142703A (en) | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
SE9900274D0 (en) | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
PT1191025E (en) * | 1999-06-30 | 2005-09-30 | Takeda Pharmaceutical | LANSOPRAZOL CRYSTALS |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
CA2409044C (en) | 2000-05-15 | 2013-02-19 | Takeda Chemical Industries, Ltd. | Improved recrystallization processes for obtaining anhydrous optically active lansoprazole |
EP1306375B1 (en) | 2000-08-04 | 2006-10-11 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and application thereof |
TW200410955A (en) * | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
DE10254167A1 (en) | 2002-11-20 | 2004-06-09 | Icon Genetics Ag | Process for the control of cellular processes in plants |
EP1575941B1 (en) | 2002-12-06 | 2012-04-11 | Nycomed GmbH | Process for preparing (S)-pantoprazole |
DK1578742T3 (en) | 2002-12-06 | 2013-01-21 | Nycomed Gmbh | PROCEDURE FOR MANUFACTURING OPTICALLY CLEAN ACTIVE COMPOUNDS |
US20070060556A1 (en) | 2003-05-05 | 2007-03-15 | Yatendra Kumar | Barium salt of benzimidazole derivative |
PE20050150A1 (en) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT |
WO2004112756A1 (en) | 2003-06-26 | 2004-12-29 | Isa Odidi | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
SE0400410D0 (en) | 2004-02-20 | 2004-02-20 | Astrazeneca Ab | New compounds |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US7601737B2 (en) | 2005-07-26 | 2009-10-13 | Nycomed Gmbh | Isotopically substituted proton pump inhibitors |
US7576219B2 (en) | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US7786309B2 (en) | 2006-06-09 | 2010-08-31 | Apotex Pharmachem Inc. | Process for the preparation of esomeprazole and salts thereof |
GB2444593B (en) | 2006-10-05 | 2010-06-09 | Santarus Inc | Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations |
US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
US7947840B2 (en) * | 2007-09-25 | 2011-05-24 | Hetero Drugs Limited | Process for preparation of enantiomerically pure esomeprazole |
EP2143722A1 (en) | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
IT1391776B1 (en) | 2008-11-18 | 2012-01-27 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF DEXLANSOPRAZOL |
IT1392813B1 (en) | 2009-02-06 | 2012-03-23 | Dipharma Francis Srl | CRYSTALLINE FORMS OF DEXLANSOPRAZOLE |
WO2011004387A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
IT1395118B1 (en) | 2009-07-29 | 2012-09-05 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE |
US9233103B2 (en) | 2011-03-25 | 2016-01-12 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR890000387B1 (en) * | 1984-09-24 | 1989-03-16 | 디 엎존 캄파니 | N-substituted derivatives of 2-(pyridylalkene-sulfinyl)benzimidazoles and process for the preparation thereof |
IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
-
1990
- 1990-11-08 DE DE19904035455 patent/DE4035455A1/en not_active Withdrawn
-
1991
- 1991-11-06 AU AU88406/91A patent/AU8840691A/en not_active Abandoned
- 1991-11-06 WO PCT/EP1991/002096 patent/WO1992008716A1/en active Search and Examination
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6953808B2 (en) | 1993-04-27 | 2005-10-11 | Sepracor Inc. | Method for treating gastric disorders using optically pure (−) pantoprazole |
WO1994025028A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole |
WO1994024867A1 (en) * | 1993-04-27 | 1994-11-10 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
US5888535A (en) * | 1993-04-27 | 1999-03-30 | Sepracor Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
EP1020461A2 (en) | 1993-05-28 | 2000-07-19 | AstraZeneca AB | Use of alkaline salts of the (-)-enantiomer of omeprazole |
EP1020460A3 (en) * | 1993-05-28 | 2003-10-15 | AstraZeneca AB | The sodium salt of the (-)-enantiomer of omeprazole |
EP1020460A2 (en) | 1993-05-28 | 2000-07-19 | AstraZeneca AB | The sodium salt of the (-)-enantiomer of omeprazole |
US5693818A (en) * | 1993-05-28 | 1997-12-02 | Astra Aktiebolag | Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole |
US5714504A (en) * | 1993-05-28 | 1998-02-03 | Astra Aktiebolag | Compositions |
EP1020461B2 (en) † | 1993-05-28 | 2015-10-21 | AstraZeneca AB | Magnesium salt of the (-)-enantiomer of omeprazole and its use |
EP1020461A3 (en) * | 1993-05-28 | 2006-10-04 | AstraZeneca AB | Use of alkaline salts of the (-)-enantiomer of omeprazole |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
US6143771A (en) * | 1993-05-28 | 2000-11-07 | Astrazeneca Ab | Compounds |
WO1994027988A1 (en) * | 1993-05-28 | 1994-12-08 | Astra Aktiebolag | Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds |
US5900424A (en) * | 1993-07-09 | 1999-05-04 | Astra Aktiebolag | Omeprazole magnesium salt form |
WO1995032959A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel dialkoxy-pyridinyl-benzimidazole derivatives |
WO1995032958A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel substituted benzimidazoles |
US5948789A (en) * | 1994-07-15 | 1999-09-07 | Astra Aktiebolag | Process for synthesis of substituted sulphoxides |
CZ297987B6 (en) * | 1994-07-15 | 2007-05-16 | Astrazeneca Ab | Process for preparing substituted sulfoxides |
WO1996002535A1 (en) * | 1994-07-15 | 1996-02-01 | Astra Aktiebolag | Process for synthesis of substituted sulphoxides |
US5840552A (en) * | 1994-11-28 | 1998-11-24 | Astra Aktiebolag | Preparation of pharmaceutically active compounds by biooxidation |
US5776765A (en) * | 1994-11-28 | 1998-07-07 | Astra Aktiebolag | Method for preparing a pharmaceutically active enantiomeric or enantiomerically enriched sulfoxide compound by enantioselective bioreduction of a racemate sulfoxide compound |
US5929244A (en) * | 1995-07-03 | 1999-07-27 | Astra Aktiebolag | Process for the optical purification of enantiomerically enriched benzimidazole derivatives |
WO1997002261A1 (en) * | 1995-07-03 | 1997-01-23 | Astra Aktiebolag | A process for the optical purification of enantiomerically enriched benzimidazole derivatives |
CN1098261C (en) * | 1995-07-03 | 2003-01-08 | 阿斯特拉曾尼卡有限公司 | Process for optical purification of enantiomerically enriched benzimidazole derivatives |
US8076361B2 (en) | 1997-05-30 | 2011-12-13 | Astrazeneca Ab | Form of S-omeprazole |
US8466175B2 (en) | 1997-05-30 | 2013-06-18 | Astrazeneca Ab | Form of S-omeprazole |
US7411070B2 (en) | 1997-05-30 | 2008-08-12 | Astrazeneca Ab | Form of S-omeprazole |
US9145389B2 (en) | 1999-06-17 | 2015-09-29 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US7569697B2 (en) | 1999-06-17 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US7737282B2 (en) | 1999-06-17 | 2010-06-15 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US8884019B2 (en) | 1999-06-17 | 2014-11-11 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US8030333B2 (en) | 1999-06-17 | 2011-10-04 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US8552198B2 (en) | 1999-06-17 | 2013-10-08 | Takeda Pharmaceutical Company Limited | Benzimidazole compound crystal |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6667323B1 (en) | 1999-08-26 | 2003-12-23 | Robert R. Whittle | Dry-blend pharmaceutical formulations |
US6653329B1 (en) | 1999-08-26 | 2003-11-25 | Robert R. Whittle | Granulated pharmaceutical formulations and methods for making the same |
US6444689B1 (en) | 1999-08-26 | 2002-09-03 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6706737B2 (en) | 1999-08-26 | 2004-03-16 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6667321B2 (en) | 1999-08-26 | 2003-12-23 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6667324B1 (en) | 1999-08-26 | 2003-12-23 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US8754108B2 (en) | 2000-11-22 | 2014-06-17 | Takeda, GmbH | Freeze-dried pantoprazole preparation and pantoprazole injection |
US9345695B2 (en) | 2001-06-01 | 2016-05-24 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8852636B2 (en) | 2001-06-01 | 2014-10-07 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8858996B2 (en) | 2001-06-01 | 2014-10-14 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
US8865190B2 (en) | 2001-06-01 | 2014-10-21 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9161920B2 (en) | 2001-06-01 | 2015-10-20 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8557285B2 (en) | 2001-06-01 | 2013-10-15 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9198888B2 (en) | 2001-06-01 | 2015-12-01 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9364439B2 (en) | 2001-06-01 | 2016-06-14 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9707181B2 (en) | 2001-06-01 | 2017-07-18 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8697097B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
US8697094B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
US9265730B2 (en) | 2002-10-16 | 2016-02-23 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
US7507829B2 (en) | 2002-12-19 | 2009-03-24 | Teva Pharmaceuticals Industries, Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
US7915423B2 (en) | 2002-12-19 | 2011-03-29 | Teva Pharmaceutical Industries, Ltd. | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
WO2004080961A2 (en) * | 2003-03-12 | 2004-09-23 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous solids of pantoprazole and processes for their preparation |
WO2004080961A3 (en) * | 2003-03-12 | 2004-12-16 | Teva Pharma | Crystalline and amorphous solids of pantoprazole and processes for their preparation |
US7683177B2 (en) | 2003-06-10 | 2010-03-23 | Teva Pharmaceutical Industries Ltd | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
WO2005012289A1 (en) * | 2003-07-17 | 2005-02-10 | Altana Pharma Ag | Novel salt of (r) - pantoprazole |
US7928240B2 (en) | 2004-04-28 | 2011-04-19 | Hetero Drugs Limited | Process for preparation of substituted sulfoxides |
WO2005105786A1 (en) * | 2004-04-28 | 2005-11-10 | Hetero Drugs Limited | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
US7176319B2 (en) | 2004-04-28 | 2007-02-13 | Hetero Drugs Limited | Process for substituted sulfoxides |
US7435826B2 (en) | 2004-04-28 | 2008-10-14 | Hetero Drugs Limited | Substituted sulfoxides |
US7928241B2 (en) | 2004-05-28 | 2011-04-19 | Hetero Drugs Limited | Stereoselective synthesis of benzimidazole sulfoxides |
US8173817B2 (en) | 2004-05-28 | 2012-05-08 | Hetero Drugs Limited | Stereoselective synthesis of benzimidazole sulfoxides |
WO2005116011A1 (en) * | 2004-05-28 | 2005-12-08 | Hetero Drugs Limited | A novel stereoselective synthesis of benzimidazole sulfoxides |
US9889152B2 (en) | 2004-06-16 | 2018-02-13 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US9238029B2 (en) | 2004-06-16 | 2016-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US7777044B2 (en) | 2005-03-03 | 2010-08-17 | Esteve Quimica, S.A. | Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1′-binaphthalene-2,2′diol |
WO2006099810A1 (en) | 2005-03-25 | 2006-09-28 | Livzon Pharmaceutical Group Inc. | Substituted sulfoxide compounds, methods for preparing the same and use thereof |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7799925B2 (en) | 2005-12-28 | 2010-09-21 | Unión Químico Farmacéutica, S.A. | Process for the preparation of the (S)-enantiomer of omeprazole |
US8404853B2 (en) | 2006-07-05 | 2013-03-26 | Lupin Limited | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds |
US8394963B2 (en) | 2007-02-21 | 2013-03-12 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
EP2842953A1 (en) | 2007-02-21 | 2015-03-04 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
US8173158B2 (en) | 2007-10-12 | 2012-05-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treating gastrointestinal disorders independent of the intake of food |
US8222422B2 (en) | 2008-03-10 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Crystal of benzimidazole compound |
US9801824B2 (en) | 2008-09-09 | 2017-10-31 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9393208B2 (en) | 2008-09-09 | 2016-07-19 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
EP2264024A1 (en) | 2008-10-14 | 2010-12-22 | LEK Pharmaceuticals d.d. | Process for the preparation of enantiomerically enriched proton pump inhibitors |
US8354541B2 (en) | 2008-11-18 | 2013-01-15 | Hetero Research Foundation | Optical purification of esomeprazole |
US8945621B2 (en) | 2009-06-25 | 2015-02-03 | Pozen Inc. | Method for treating a patient at risk for developing an NSAID-associated ulcer |
WO2011058569A1 (en) | 2009-11-12 | 2011-05-19 | Hetero Research Foundation | Process for the resolution of omeprazole |
US8748619B2 (en) | 2009-11-12 | 2014-06-10 | Hetero Research Foundation | Process for the resolution of omeprazole |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US9987231B2 (en) | 2011-12-28 | 2018-06-05 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US10603283B2 (en) | 2011-12-28 | 2020-03-31 | Genus Lifesciences, Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
RU2726320C1 (en) * | 2020-02-09 | 2020-07-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) | Method for determining omeprazole impurity components |
Also Published As
Publication number | Publication date |
---|---|
AU8840691A (en) | 1992-06-11 |
WO1992008716A1 (en) | 1992-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4035455A1 (en) | ENANTIOMER SEPARATION | |
DE60216823T2 (en) | Intermediates for the preparation of pyridazinone aldose reductase inhibitors. | |
DE69722027T2 (en) | CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF | |
DD273833A5 (en) | N 9 - CYCLOPENTYL SUBSTITUTED ADENINE DERIVATIVES | |
DE60120138T2 (en) | AMID COMPOUNDS AND ITS USE | |
DE3331808A1 (en) | CARBOSTYRIL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM | |
DE2940833C2 (en) | ||
EP0114270B1 (en) | Acyl derivatives of 1,4:3,6-dianhydro-hexitoles, method for their preparation and their pharmazeutical use | |
DD263774A5 (en) | PROCESS FOR PREPARING A NEW 1H, 3H-PYRROLO-1,2-C-THIAZOLE DERIVATIVE | |
DE60025327T2 (en) | 6-ARYLPHENANTHRIDINE WITH PDE-IV HEMMENDER EFFECT | |
DE19615232A1 (en) | New carbamoyl derivatives and their use as 5-HT ¶1¶¶A¶ antagonists | |
DE4132632A1 (en) | SUBSTITUTED IMIDAZOLYL-PROPENSAEUREDERIVATE | |
DE4132633A1 (en) | CYCLICALLY SUBSTITUTED IMIDAZOLYL-PROPENEASE DERIVATIVES | |
DE69916066T2 (en) | NEW BENZOXAZOLE WITH PDE-INHIBITOR EFFECT | |
DD294935A5 (en) | METHOD FOR THE PRODUCTION OF HALOGEN-SUBSTITUTED DIPHENYLSULFIDES AND A PHARMACEUTICAL PREPARATION CONTAINING THEM | |
EP0628310A1 (en) | Use of partially known substituted chromanes as medicine, new products and process for their preparation | |
DE60213087T2 (en) | Pyrimidine derivatives as selective inhibitors of COX-2 | |
EP0104423A1 (en) | 2-Nitro-ethene diamines, process for their preparation and their use as medicines | |
EP0819688A1 (en) | 4-substituted benzofuranes | |
DE60305053T2 (en) | Pyrimidine derivatives as selective COX-2 inhibitors | |
DE3049959C2 (en) | ||
DE3141387C2 (en) | ||
EP0621037B1 (en) | Pyrido-pyrimidinediones, process for their preparation and their use as pharmaceuticals | |
EP0608709A1 (en) | 2-Oxo-quinolin-1-yl-methyl-phenylacetic acid derivatives as angiotensin II Antagonists | |
EP0665228A1 (en) | Pharmaceutical compositions containing 3-phenylsulfonyl-3,7-diazabicyclo 3,3,1 nonanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |